Search

Your search keyword '"Nair, Gonasagrie"' showing total 6 results
Start Over Author "Nair, Gonasagrie" Publisher massachusetts medical society
6 results on '"Nair, Gonasagrie"'

1. Timing of initiation of antiretroviral drugs during tuberculosis therapy

Author

Karim, Salim S. Abdool, Naidoo, Kogieleum, Grobler, Anneke, Padayatchi, Nesri, Baxter, Cheryl, Gray, Andrew, Gengiah, Tanuja, Nair, Gonasagrie, Bamber, Sheila, Singh, Aarthi, Khan, Munira, Pienaar, Jacqueline, El-Sadr, Wafaa, Friedland, Gerald, and Karim, Quarraisha Abdool

Subjects
Antiviral agents -- Usage, Antiviral agents -- Health aspects, Tuberculosis -- Care and treatment
Abstract

A study was conducted to evaluate whether timely initiation of antiretroviral drugs during tuberculosis therapy was effective in reducing mortality and improving survival rates among patients with tuberculosis and human immunodeficiency virus (HIV). Results indicated that the use of such therapy greatly improved survival rates among such patients.

Published
2010

2. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women

Author

Baeten, Jared M., primary, Palanee-Phillips, Thesla, additional, Brown, Elizabeth R., additional, Schwartz, Katie, additional, Soto-Torres, Lydia E., additional, Govender, Vaneshree, additional, Mgodi, Nyaradzo M., additional, Matovu Kiweewa, Flavia, additional, Nair, Gonasagrie, additional, Mhlanga, Felix, additional, Siva, Samantha, additional, Bekker, Linda-Gail, additional, Jeenarain, Nitesha, additional, Gaffoor, Zakir, additional, Martinson, Francis, additional, Makanani, Bonus, additional, Pather, Arendevi, additional, Naidoo, Logashvari, additional, Husnik, Marla, additional, Richardson, Barbra A., additional, Parikh, Urvi M., additional, Mellors, John W., additional, Marzinke, Mark A., additional, Hendrix, Craig W., additional, van der Straten, Ariane, additional, Ramjee, Gita, additional, Chirenje, Zvavahera M., additional, Nakabiito, Clemensia, additional, Taha, Taha E., additional, Jones, Judith, additional, Mayo, Ashley, additional, Scheckter, Rachel, additional, Berthiaume, Jennifer, additional, Livant, Edward, additional, Jacobson, Cindy, additional, Ndase, Patrick, additional, White, Rhonda, additional, Patterson, Karen, additional, Germuga, Donna, additional, Galaska, Beth, additional, Bunge, Katherine, additional, Singh, Devika, additional, Szydlo, Daniel W., additional, Montgomery, Elizabeth T., additional, Mensch, Barbara S., additional, Torjesen, Kristine, additional, Grossman, Cynthia I., additional, Chakhtoura, Nahida, additional, Nel, Annalene, additional, Rosenberg, Zeda, additional, McGowan, Ian, additional, and Hillier, Sharon, additional

Published
2016
Full Text
View/download PDF

3. Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women

Author

Marrazzo, Jeanne M., primary, Ramjee, Gita, additional, Richardson, Barbra A., additional, Gomez, Kailazarid, additional, Mgodi, Nyaradzo, additional, Nair, Gonasagrie, additional, Palanee, Thesla, additional, Nakabiito, Clemensia, additional, van der Straten, Ariane, additional, Noguchi, Lisa, additional, Hendrix, Craig W., additional, Dai, James Y., additional, Ganesh, Shayhana, additional, Mkhize, Baningi, additional, Taljaard, Marthinette, additional, Parikh, Urvi M., additional, Piper, Jeanna, additional, Mâsse, Benoît, additional, Grossman, Cynthia, additional, Rooney, James, additional, Schwartz, Jill L., additional, Watts, Heather, additional, Marzinke, Mark A., additional, Hillier, Sharon L., additional, McGowan, Ian M., additional, and Chirenje, Z. Mike, additional

Published
2015
Full Text
View/download PDF

4. Integration of Antiretroviral Therapy with Tuberculosis Treatment

Author

Abdool Karim, Salim S., primary, Naidoo, Kogieleum, additional, Grobler, Anneke, additional, Padayatchi, Nesri, additional, Baxter, Cheryl, additional, Gray, Andrew L., additional, Gengiah, Tanuja, additional, Gengiah, Santhanalakshmi, additional, Naidoo, Anushka, additional, Jithoo, Niraksha, additional, Nair, Gonasagrie, additional, El-Sadr, Wafaa M., additional, Friedland, Gerald, additional, and Abdool Karim, Quarraisha, additional

Published
2011
Full Text
View/download PDF

5. Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy

Author

Abdool Karim, Salim S., primary, Naidoo, Kogieleum, additional, Grobler, Anneke, additional, Padayatchi, Nesri, additional, Baxter, Cheryl, additional, Gray, Andrew, additional, Gengiah, Tanuja, additional, Nair, Gonasagrie, additional, Bamber, Sheila, additional, Singh, Aarthi, additional, Khan, Munira, additional, Pienaar, Jacqueline, additional, El-Sadr, Wafaa, additional, Friedland, Gerald, additional, and Abdool Karim, Quarraisha, additional

Published
2010
Full Text
View/download PDF

6. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.

Author

Bekker LG, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, Gill K, Harkoo I, Jaggernath M, Kigozi G, Kiwanuka N, Kotze P, Lebina L, Louw CE, Malahleha M, Manentsa M, Mansoor LE, Moodley D, Naicker V, Naidoo L, Naidoo M, Nair G, Ndlovu N, Palanee-Phillips T, Panchia R, Pillay S, Potloane D, Selepe P, Singh N, Singh Y, Spooner E, Ward AM, Zwane Z, Ebrahimi R, Zhao Y, Kintu A, Deaton C, Carter CC, Baeten JM, and Matovu Kiweewa F

Abstract

Background: There are gaps in uptake of, adherence to, and persistence in the use of preexposure prophylaxis for human immunodeficiency virus (HIV) prevention among cisgender women., Methods: We conducted a phase 3, double-blind, randomized, controlled trial involving adolescent girls and young women in South Africa and Uganda. Participants were assigned in a 2:2:1 ratio to receive subcutaneous lenacapavir every 26 weeks, daily oral emtricitabine-tenofovir alafenamide (F/TAF), or daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF; active control); all participants also received the alternate subcutaneous or oral placebo. We assessed the efficacy of lenacapavir and F/TAF by comparing the incidence of HIV infection with the estimated background incidence in the screened population and evaluated relative efficacy as compared with F/TDF., Results: Among 5338 participants who were initially HIV-negative, 55 incident HIV infections were observed: 0 infections among 2134 participants in the lenacapavir group (0 per 100 person-years; 95% confidence interval [CI], 0.00 to 0.19), 39 infections among 2136 participants in the F/TAF group (2.02 per 100 person-years; 95% CI, 1.44 to 2.76), and 16 infections among 1068 participants in the F/TDF group (1.69 per 100 person-years; 95% CI, 0.96 to 2.74). Background HIV incidence in the screened population (8094 participants) was 2.41 per 100 person-years (95% CI, 1.82 to 3.19). HIV incidence with lenacapavir was significantly lower than background HIV incidence (incidence rate ratio, 0.00; 95% CI, 0.00 to 0.04; P<0.001) and than HIV incidence with F/TDF (incidence rate ratio, 0.00; 95% CI, 0.00 to 0.10; P<0.001). HIV incidence with F/TAF did not differ significantly from background HIV incidence (incidence rate ratio, 0.84; 95% CI, 0.55 to 1.28; P = 0.21), and no evidence of a meaningful difference in HIV incidence was observed between F/TAF and F/TDF (incidence rate ratio, 1.20; 95% CI, 0.67 to 2.14). Adherence to F/TAF and F/TDF was low. No safety concerns were found. Injection-site reactions were more common in the lenacapavir group (68.8%) than in the placebo injection group (F/TAF and F/TDF combined) (34.9%); 4 participants in the lenacapavir group (0.2%) discontinued the trial regimen owing to injection-site reactions., Conclusions: No participants receiving twice-yearly lenacapavir acquired HIV infection. HIV incidence with lenacapavir was significantly lower than background HIV incidence and HIV incidence with F/TDF. (Funded by Gilead Sciences; PURPOSE 1 ClinicalTrials.gov number, NCT04994509.)., (Copyright © 2024 Massachusetts Medical Society.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results